The National Institute for Health and Care Excellence

MHRA and NICE aligned pathway: how it's working in practice

Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...
National Institute for Health and Care Excellence

Weekly insulin jab could cut injections from 365 a year to just 52

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation today (Thursday, 20 August). The switch could cut the ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment HTG781 17 September 2026 17 September 2026 ...
National Institute for Health and Care Excellence

Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable

There is a simple discount patient access scheme for ibrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Dementia: assessment, management and support for people living with dementia and their carers

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies

There is a simple discount patient access scheme for marstacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies

Marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 ...
National Institute for Health and Care Excellence

Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

There is a commercial access agreement for vanzacaftor-tezacaftor-deutivacaftor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.
National Institute for Health and Care Excellence

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

There is a simple discount patient access scheme for teclistamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...